Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.50 |
| ▸ | HMGCR | P04035 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845876 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL31317692 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL28249427 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL3503759 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL28336578 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL9336107 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL28250106 | 0.98 | PTPN7 (0.48) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL158657 | 0.98 | PTPN7 (0.47) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| SCHEMBL28200583 | 0.98 | PTPN7 (0.47) | PTPN7HMGCRRECQLTDP1EPHX2 | |
| Bicarbonate SCHEMBL1867009 | 0.96 | PTPN7 (0.52) | PTPN7HMGCRRECQLTDP1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | GIVAUDAN SA (CH) | 2026-03-31 | — | — | US | claimed |
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4695016-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-4302747-B1 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | OREAL (FR) | 2026-01-14 | — | — | EP | claimed |
| US-20250302728-A1 | FRAGRANCE COMPOSITIONS AND PRODUCTS CONVEYING A POSITIVE MOOD | SYMRISE AG (DE) | 2025-10-02 | — | — | US | claimed |
| WO-2025202258-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-02 | — | — | WO | claimed |
| EP-4608360-A1 | ANTI-DANDRUFF COMPOSITIONS | Firmenich SA (CH) | 2025-09-03 | — | — | EP | claimed |
| CN-120130641-A | Liquid watermelon essence and preparation method and application thereof | 广州启云生物有限公司 | 2025-06-13 | — | — | CN | claimed |
| EP-4526411-A1 | FRAGRANCE COMPOSITIONS AND PRODUCTS CONVEYING A POSITIVE MOOD | Symrise AG (DE) | 2025-03-26 | — | — | EP | claimed |
| US-12239209-B2 | System for dispensing a cosmetic product | L'OREAL (FR) | 2025-03-04 | — | — | US | claimed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | claimed |
| US-7348396-B2 | Modified polyethylenephosphinic acids and their salts | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2008-03-25 | — | — | US | claimed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| WO-2007025402-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| US-20070027297-A1 | Modified polyethylenephosphinic acids and their salts | CLARIANT FINANCE (BVI) LIMITED | 2007-02-01 | — | — | US | claimed |
| US-20040176580-A1 | Modified polyethylenephosphinic acids and their salts | CLARIANT GMBH | 2004-09-09 | — | — | US | claimed |
| US-6600067-B2 | Reacting phosphorous acid (H3PO3) directly with alkynes | CLARIANT GMBH (DE) | 2003-07-29 | — | — | US | claimed |
| US-6583315-B2 | Reacting yellow elemental phosphorus with an alkyl halide under alkaline conditions; acidifying, esterifying, isolating and hydrolyzing to obtain purified alkylphosphonous acid; reacting with acetylene | CLARIANT GMBH (DE) | 2003-06-24 | — | — | US | claimed |
| US-20030073865-A1 | PROCESS FOR PREPARING ETHANEBIS(ALKYLPHOSPHINIC) ACIDS | CLARIANT GMBH | 2003-04-17 | — | — | US | claimed |
| US-20020082447-A1 | Process for preparing ethylenediphosphonic acids | CLARIANT GMBH | 2002-06-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | CUTA, EXOC1, EXOSC10 | PTPN7 2707/4885HMGCR 3945/4885RECQL 2976/4885 |
| US-20040176580-A1 | Modified polyethylenephosphinic acids and their salts | PHOSPHO1, PTEN, PBRM1 | PTPN7 549/4885HMGCR 2567/4885RECQL 2844/4885 |
| US-20030073865-A1 | PROCESS FOR PREPARING ETHANEBIS(ALKYLPHOSPHINIC) ACIDS | HAO2, ARSA, APEH | PTPN7 1841/4885HMGCR 1844/4885RECQL 1326/4885 |
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | PTPN7 4151/4885HMGCR 874/4885RECQL 4466/4885 |
| US-12239209-B2 | System for dispensing a cosmetic product | PDE12, SAMM50, POLR1C | PTPN7 2644/4885HMGCR 1462/4885RECQL 117/4885 |
| US-20020082447-A1 | Process for preparing ethylenediphosphonic acids | ENPP1, ALK, INPPL1 | PTPN7 788/4885HMGCR 2950/4885RECQL 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.